Autopsy report · NCT01741155
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Cause of deathSlow enrollment
“The study did not meet efficacy end point and did not enroll patients in the randomized phase.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 2 years 2 months before it stopped.
- 34 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Sponsor type
- Industry
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- SPI-1620; Docetaxel
- Participants
- 34
- Sites
- 5
- Countries
- United States
Trials that died the same way
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
“The study did not meet endpoint.” - Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
“This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.” - A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
“The study did not meet the primary endpoint.” - DASH - Decision Making in Adolescent Sexual Health
“This research was not conducted at UNM \& not Applicable Clinical Trial.” - A Study of LY3405105 in Participants With Advanced Cancer
“The study was terminated for lack of sufficient efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.